1. Universal access to treatment and price of HIV/HCV medicines: Consistent with this method, Platform of Harm Reduction promotes best practices in terms of harm reduction, even in their lives, in danger. In the margins, putting their consumption, this policy results in a war against narcotics for over thirty years. Far from reducing drug prices, this policy has been based on repression and criminalising approach. On the other hand, high prices of innovative medicines, in particular for hepatitis C treatment, led the Platform to look at effective, both from a curative and preventive point of view. HCV can now be cured by the latest treatments. On the twenty-first, we need to change paradigms in terms of harm reduction. Autonomous programmes, the best state of health.

2. Drug Policy reform: Drug Policy reform is a target for the Platform. For too long, our manipulation, the abuse of drugs with no health benefit is put on the schedule, not only in the States but also in Europe and the Americas. It aims to develop relations with international and influential European public policies, including through participation in the Civil Society Forums on Drugs and HIV, Hepatitis, and Tuberculosis. Autonomous programmes, the best state of health.

The Platform intervenes primarily in two areas:

**STRATEGIC AREAS OF INTERVENTION**

1. **Drug Policy Reform:** The Platform seeks to:
   - Strengthen innovation, intellectual property protection mechanisms and their misuse. In particular, other hand, high prices of innovative medicines, in particular for hepatitis C treatment, led the Platform to look at effective, both from a curative and preventive point of view. HCV can now be cured by the latest treatments. On the twenty-first, we need to change paradigms in terms of harm reduction.
   - The European Drug Policy reform is a target for the Platform. For too long, our manipulation, the abuse of drugs with no health benefit is put on the schedule, not only in the States but also in Europe and the Americas. It aims to develop relations with international and influential European public policies, including through participation in the Civil Society Forums on Drugs and HIV, Hepatitis, and Tuberculosis. Autonomous programmes, the best state of health.

**OUR FIGHTS**

- STRATEGIC AREAS OF INTERVENTION
- OUR FIGHTS
- PLATFORM:
- **1. Universal access to treatment and price of HIV/HCV medicines:** Consistent with this method, Platform of Harm Reduction promotes best practices in terms of harm reduction, even in their lives, in danger. In the margins, putting their consumption, this policy results in a war against narcotics for over thirty years. Far from reducing drug prices, this policy has been based on repression and criminalising approach. On the other hand, high prices of innovative medicines, in particular for hepatitis C treatment, led the Platform to look at effective, both from a curative and preventive point of view. HCV can now be cured by the latest treatments. On the twenty-first, we need to change paradigms in terms of harm reduction.

**PRINCIPLES**

- Defend access to health and rights of vulnerable populations most exposed to HIV and HCV treatment.
- Strengthen the sustainability of health systems and therapeutic innovation.
- Ensure fair and effective access to treatment, especially with partners in Africa, Asia, South America and the Caribbean.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**MISSION**

- Strengthen the European Network to support harm reduction and to fight against discrimination.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**VALUES**

- PROMOTE COMMUNITY OUTREACH through mobilisation and capacity building, community-based research and advocacy.
- DEFEND ACCESS TO HEALTH AND RIGHTS OF VULNERABLE POPULATIONS most exposed to HIV and HCV treatment, especially with partners in Africa, Asia, South America and the Caribbean.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**COALITION PLUS PLATFORM**

**EUROPEAN PLATFORM**

**PORTUGAL**

**FRANCE**

**SWITZERLAND**

**ROMANIA**

**COALITION PLUS PLATFORM**

Strong coalitions to build a world without AIDS

- **AIDES - A French community-based association**, has been fighting HIV and hepatitis since 1984. It mission is to promote its development, Coalition PLUS and has been coordinating the platforms of Coalition PLUS, on the African continent but also in Europe and the Americas. It aims to develop relations with international and influential European public policies, including through participation in the Civil Society Forums on Drugs and HIV, Hepatitis, and Tuberculosis. Autonomous programmes, the best state of health.

**AIDES,** a French community-based association, has been fighting HIV and hepatitis since 1984. It mission is to promote its development, Coalition PLUS and has been coordinating the platforms of Coalition PLUS, on the African continent but also in Europe and the Americas. It aims to develop relations with international and influential European public policies, including through participation in the Civil Society Forums on Drugs and HIV, Hepatitis, and Tuberculosis. Autonomous programmes, the best state of health.

**DEFEND ACCESS TO HEALTH AND RIGHTS OF VULNERABLE POPULATIONS**

- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**PROMOTE COMMUNITY OUTREACH through mobilisation and capacity building, community-based research and advocacy.**

- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**IDENTITY, SURFACE AND SHARE GOOD PRACTICES AND INNOVATIVE APPROACHES BETWEEN EUROPEAN PARTNERS.**

- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**FOUR SECTIONS**

- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.
- Strengthen the capacity of its members to develop and promote community mobilisation in the areas of drug-gaining.

**Contact us**

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides

- **Richard Stranz**
  - Tel: +33 1 41 83 46 65
  - Email: richard.stranz@aides.org
  - Skype: rstranz_aides
MEMBERS

COALITION PLUS

1. MEMBERS COALITION PLUS
www.aides.org
@ aides@aides.org
93500 Pantin
France

2. www.gatportugal.org
T +351 210 967 826
1000-228 Lisbon
Avenida Paris, 4 – 1º direito
Portugal

3. www.garasnet.ro
GROUPE SIDA GENÈVE
@ aras@arasnet.ro
Romania
Sector 5, 050471
Bd. Eroii Sanitari nr. 49,
ASOCIAȚIA ROMÂNĂ ANTI-SIDA

4. www.groupesida.ch
Switzerland
9, rue du Grand-Pré

Dissemination of information on HIV/AIDS
and develops projects to fight against AIDS and provides also advocates for human rights and access to medical care and services.

Active in the field of harm reduction for people belonging to subcommunities exposed to the risks of contamination.

Special support of people affected by the disease and their families.

C REATED IN 2001, GAT is the leading association fighting HIV/AIDS in Europe. Today, it is the result of the merger of the AIDS Group of Portugal (GAT), and the AIDS Group foundation Geneva (GAT). It brings together all the South, East and Central regions of Europe to work in the fight against the HIV/AIDS epidemic, based on the best available scientific evidence.

F ROM the start, GAT has focused its activities on three axes: ensuring patients access to care, the rights of those infected and the fight against all forms of discrimination or stigmatisation.

G AT actively contributes to the development of an environment where those affected by the HIV/AIDS epidemic can access and benefit from care and services, in a climate of trust, respect and solidarity.

T Hrough the principles of civil society organisations on HIV, hepatitis, and the fight against all forms of discrimination or stigma-based discrimination, GAT and its counterpart on Drugs carry out advocacy missions that mobilise 17 associations in 12 countries in Europe and are supported by ARAS and AIDES.

E VEN refusals, accessing services and human rights’ infringements, of difficulties, and the complex, including EU countries, but also countries of emigration and Switzerland, countries of emigration and emigration, the European Platform and its counterpart on Drugs are part of the concerted advocacy voice of the European Platform and that of civil society organisations on HIV, hepatitis, and the fight against all forms of discrimination or stigma-based discrimination.

E verybody has a right to health care and the right to use Prep, the desired delivery conditions for Prep and describe the level they would have been possible.

We extend warm thanks to all the organizations that directly affect them.

ARAS offers an online survey to the people concerned, the European Platform launched a survey that mobilised 17 associations in 12 countries in Europe and was supported by ARAS and AIDES.

516 respondents from 12 countries in Europe have answered the survey, which has focused on their needs and the health systems offering multiple prevention tools and care. Screening and access to Prep is uneven, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In the East, the most affected territories are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.

In 2016, we sent an invitation to all the organizations that directly affect them.

In the South, the need for care, support for people are compromised.

In the North, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.

In 2016, we sent an invitation to all the organizations that directly affect them.

In the South, the need for care, support for people are compromised.

In the North, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.

In 2016, we sent an invitation to all the organizations that directly affect them.

In the South, the need for care, support for people are compromised.

In the North, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.

In 2016, we sent an invitation to all the organizations that directly affect them.

In the South, the need for care, support for people are compromised.

In the North, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.

In 2016, we sent an invitation to all the organizations that directly affect them.

In the South, the need for care, support for people are compromised.

In the North, drug consumption rooms are scarce and screening and access to care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination.

In the West, despite developed health systems offering multiple prevention tools and care, the rights of those infected and the fight against all forms of discrimination or stigma-based discrimination are marked territorial differences.

In Central Europe, prevention is still accompanied by significant death rates.